
Opinion|Videos|May 15, 2024
In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs
Selina McGee, OD, FAAO, evaluates the cost and efficacy of in-office procedures like microblepharoexfoliation, the potential clinical and economic costs associated with delaying access to the FDA-approved treatment through prior authorization or mandating prior use of traditional over-the-counter therapies like tea tree oil and lid wipes, and considers impact on patient adherence.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
4
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
5

























